These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28895186)

  • 1. The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.
    Frisaldi E; Carlino E; Zibetti M; Barbiani D; Dematteis F; Lanotte M; Lopiano L; Benedetti F
    Mov Disord; 2017 Oct; 32(10):1474-1478. PubMed ID: 28895186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teaching neurons to respond to placebos.
    Benedetti F; Frisaldi E; Carlino E; Giudetti L; Pampallona A; Zibetti M; Lanotte M; Lopiano L
    J Physiol; 2016 Oct; 594(19):5647-60. PubMed ID: 26861164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic treatment modulates sensory attenuation at the onset of the movement in Parkinson's disease: A test of a new framework for bradykinesia.
    Macerollo A; Chen JC; Korlipara P; Foltynie T; Rothwell J; Edwards MJ; Kilner JM
    Mov Disord; 2016 Jan; 31(1):143-6. PubMed ID: 26749120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
    Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B
    Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA; Sabach T; Melamed E; Djaldetti R
    Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
    Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
    Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.
    Müller T; Benz S; Börnke C; Przuntek H
    Acta Neurol Scand; 2004 May; 109(5):348-54. PubMed ID: 15080862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the clinical pharmacology of Parkinson's disease.
    Montastruc JL
    Therapie; 1991; 46(4):293-303. PubMed ID: 1683024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.
    LeWitt PA; Hauser RA; Grosset DG; Stocchi F; Saint-Hilaire MH; Ellenbogen A; Leinonen M; Hampson NB; DeFeo-Fraulini T; Freed MI; Kieburtz KD
    Mov Disord; 2016 Sep; 31(9):1356-65. PubMed ID: 27090868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies.
    Trenkwalder C; Stocchi F; Poewe W; Dronamraju N; Kenney C; Shah A; von Raison F; Graf A
    Mov Disord; 2016 Jul; 31(7):1054-8. PubMed ID: 27214258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
    Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
    Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease.
    Wolters EC; Calne DB
    CMAJ; 1989 Mar; 140(5):507-14. PubMed ID: 2563667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
    Vitek JL; Bakay RA; Freeman A; Evatt M; Green J; McDonald W; Haber M; Barnhart H; Wahlay N; Triche S; Mewes K; Chockkan V; Zhang JY; DeLong MR
    Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
    Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
    Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.